Literature DB >> 21909801

Systemic lupus erythematosus, the brain, and anti-NR2 antibodies.

Maria B Lauvsnes1, Roald Omdal.   

Abstract

Neurological and psychiatric disorders are common in patients with systemic lupus erythematosus (SLE). While several pathogenetic mechanisms are thought to be involved, among of the most challenging and best investigated are antibodies against the N-methyl-D: -aspartate (NMDA) receptor subtypes 2a and 2b (anti-NR2 antibodies). This review summarizes the most relevant mechanisms for neuropsychiatric (NP) involvement in SLE (NPSLE) with special emphasis on the role of anti-NR2 antibodies and provides an overview of published articles on anti-NR2 antibodies and brain involvement as of May 2011. In mice, neuronal cell death occurs when anti-NR2 antibodies gain access to the brain, either by injection directly into the brain, or by systemic immunization and abrogation of the blood-brain barrier. Either impaired memory and hippocampal atrophy, or emotional disturbances and atrophy of the amygdala follow, seemingly dependent on the method used for disruption of the blood-brain barrier. Recent studies indicate that the effect of anti-NR2 antibodies is dose dependent; at low concentrations they alter synaptic function; at higher concentrations they can cause neuronal cell death by apoptosis. An association between anti-NR2 antibodies and NPSLE has been confirmed in 6 out of 13 human studies; the manifestations are primarily of diffuse cerebral character.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909801     DOI: 10.1007/s00415-011-6232-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  76 in total

Review 1.  Ligand-gated ion channel interactions with cytoskeletal and signaling proteins.

Authors:  M Sheng; D T Pak
Journal:  Annu Rev Physiol       Date:  2000       Impact factor: 19.318

Review 2.  Glutamate receptors in the mammalian central nervous system.

Authors:  S Ozawa; H Kamiya; K Tsuzuki
Journal:  Prog Neurobiol       Date:  1998-04       Impact factor: 11.685

3.  Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus.

Authors:  Takahisa Gono; Yasushi Kawaguchi; Hirotaka Kaneko; Katsuji Nishimura; Masanori Hanaoka; Sayuri Kataoka; Yuko Okamoto; Yasuhiro Katsumata; Hisashi Yamanaka
Journal:  Rheumatology (Oxford)       Date:  2011-01-05       Impact factor: 7.580

4.  Antibodies against N-methyl-D-aspartate receptors in patients with systemic lupus erythematosus without major neuropsychiatric syndromes.

Authors:  Elizabeth Kozora; Sterling G West; Steven F Maier; Christopher M Filley; David B Arciniegas; Mark Brown; David Miller; Alex Grimm; Lening Zhang
Journal:  J Neurol Sci       Date:  2010-05-23       Impact factor: 3.181

5.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

Authors:  John G Hanly; Grace McCurdy; Lisa Fougere; Jo-Anne Douglas; Kara Thompson
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

6.  Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

Authors:  R L Brey; S L Holliday; A R Saklad; M G Navarrete; D Hermosillo-Romo; C L Stallworth; C R Valdez; A Escalante; I del Rincón; G Gronseth; C B Rhine; P Padilla; D McGlasson
Journal:  Neurology       Date:  2002-04-23       Impact factor: 9.910

7.  Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study.

Authors:  H Ainiala; P Dastidar; J Loukkola; T Lehtimäki; M Korpela; J Peltola; A Hietaharju
Journal:  Scand J Rheumatol       Date:  2005 Sep-Oct       Impact factor: 3.641

8.  Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement.

Authors:  S Hirohata; T Miyamoto
Journal:  Arthritis Rheum       Date:  1990-05

9.  In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death.

Authors:  M-A Martel; D J A Wyllie; G E Hardingham
Journal:  Neuroscience       Date:  2008-03-04       Impact factor: 3.590

10.  Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis.

Authors:  Hilda Fragoso-Loyo; Javier Cabiedes; Alejandro Orozco-Narváez; Luis Dávila-Maldonado; Yemil Atisha-Fregoso; Betty Diamond; Luis Llorente; Jorge Sánchez-Guerrero
Journal:  PLoS One       Date:  2008-10-06       Impact factor: 3.240

View more
  36 in total

Review 1.  Inflammation and the two-hit hypothesis of schizophrenia.

Authors:  Keith A Feigenson; Alex W Kusnecov; Steven M Silverstein
Journal:  Neurosci Biobehav Rev       Date:  2013-11-15       Impact factor: 8.989

2.  Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Authors:  Gaurav Gulati; Philip H Iffland; Damir Janigro; Bin Zhang; Michael E Luggen
Journal:  Clin Rheumatol       Date:  2016-06-29       Impact factor: 2.980

3.  Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain.

Authors:  Amy J Gleichman; Lynn A Spruce; Josep Dalmau; Steven H Seeholzer; David R Lynch
Journal:  J Neurosci       Date:  2012-08-08       Impact factor: 6.167

Review 4.  Psychosis: an autoimmune disease?

Authors:  Adam A J Al-Diwani; Thomas A Pollak; Sarosh R Irani; Belinda R Lennox
Journal:  Immunology       Date:  2017-08-03       Impact factor: 7.397

Review 5.  The blood brain barrier and neuropsychiatric lupus: new perspectives in light of advances in understanding the neuroimmune interface.

Authors:  Ariel D Stock; Sivan Gelb; Ofer Pasternak; Ayal Ben-Zvi; Chaim Putterman
Journal:  Autoimmun Rev       Date:  2017-04-17       Impact factor: 9.754

Review 6.  Integrative neuroscience approach to neuropsychiatric lupus.

Authors:  Patricio T Huerta; Elizabeth L Gibson; Carson Rey; Tomás S Huerta
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

7.  Tertiary lymphoid structures in the choroid plexus in neuropsychiatric lupus.

Authors:  Ariel D Stock; Evan Der; Sivan Gelb; Michelle Huang; Karen Weidenheim; Ayal Ben-Zvi; Chaim Putterman
Journal:  JCI Insight       Date:  2019-06-06

Review 8.  Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome.

Authors:  José Fidel Baizabal-Carvallo; Cecilia Bonnet; Joseph Jankovic
Journal:  J Neural Transm (Vienna)       Date:  2013-04-13       Impact factor: 3.575

Review 9.  Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.

Authors:  Mia Levite
Journal:  J Neural Transm (Vienna)       Date:  2014-08-01       Impact factor: 3.575

Review 10.  Diagnosis and management of neuropsychiatric SLE.

Authors:  John G Hanly
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.